

Not estimable

Not estimable

0.1

Lower Incidence Higher Incidence

100.0% 0.01 [0.00, 0.02]

Robert et al, 2015

Weber et al, 2015


Total (95% CI)

0


Heterogeneity: Chi2 = 4.29, df = 3 (P = 0.23); I2 = 30%

Test for overall effect: Z = 9.97 (P < 0.00001)


**Supplementary figure 1** Forest plots of incidence of high-grade anemia (**A**), thrombocytopenia (**B**), leukopenia (**C**) and neutropenia (**D**) during PD-1 inhibitor monotherapy.



**Supplementary figure 2** Forest plots of incidence of high-grade anemia during PD-1 inhibitor monotherapy for NSCLC (**A**), melanoma (**B**), RCC (**C**), urothelial carcinoma (**D**), and HNSCC (**E**).



**Supplementary figure 3** Forest plots of incidence of all-grade leukopenia for NSCLC (**A**) and melanoma (**B**); all-grade neutropenia for NSCLC (**C**) and melanoma (**D**); all-grade thrombocytopenia for NSCLC (**E**) and melanoma (**F**) during PD-1 inhibitor monotherapy.



**Supplementary figure 4** Funnel plots for PD-1 inhibitor monotherapy studies for all tumor types (**A**) and NSCLC (**B**) for anemia of all grades.